Wiki Article
ABS-201
Nguồn dữ liệu từ Wikipedia, hiển thị bởi DefZone.Net
| Clinical data | |
|---|---|
| Other names | ABS201 |
| Routes of administration | Subcutaneous injection[1] |
| Drug class | Prolactin receptor monoclonal antibody |
| ATC code |
|
ABS-201 is a monoclonal antibody against the prolactin receptor (PRLR) which is under development for the treatment of androgenic alopecia (hair loss) and endometriosis.[1][2][3][4] It is taken by long-lasting subcutaneous injection.[1][3]
The drug is claimed to work by activating dormant hair follicles and causing them to move from the telogen phase to the anagen phase.[3][4] ABS-201 has been found to produce robust hair regrowth in mice and balding macaques that was greater than that with minoxidil.[3][4] It might also be able to reverse greying of hair.[3]
ABS-201 is under development by AbSci.[1][2] As of October 2025, it is in the preclinical research stage of development for alopecia.[1][3] A phase 1/2a clinical trial for alopecia is being planned for late 2025 or early 2026.[1][3] The development of ABS-201 is being overseen by prominent hair loss researcher Rodney Sinclair.[3] The chemical structure of the drug does not yet appear to have been disclosed.[1]
See also
[edit]- List of investigational hair loss drugs
- BAY-1158061 (HMI-115)
- PP405 and ET-02 (RS-5441)
References
[edit]- ^ a b c d e f g "ABS 201". AdisInsight. 7 October 2025. Retrieved 14 November 2025.
- ^ a b "Delving into the Latest Updates on ABS-201(Absci Corp) with Synapse". Synapse. 25 October 2025. Retrieved 14 November 2025.
- ^ a b c d e f g h Frederickson E (20 October 2025). "A New Hair Loss Drug Could Cure Balding and Reverse Graying". Popular Mechanics. Retrieved 14 November 2025.
- ^ a b c Kahn A (2024). "Absci 2024 R&D Day Presentation". Absci Corporation.